HeartSciences Inc. 8K

HeartSciences filed a preliminary proxy for its proposed combination with Fortitude Mining Holdings, including a large share issuance to DCG and a possible reverse stock split, while reporting minimal Fiscal 2026 revenue and updating on its AI-ECG product and FDA submission progress.

On July 29, 2026, HeartSciences Inc. announced that it filed a preliminary proxy statement with the SEC for its previously disclosed proposed business combination with Fortitude Mining Holdings, Inc., outlining a structure that includes issuing approximately 107.6 million shares of newly designated Class V Common Stock to Digital Currency Group (Fortitude’s parent) and presenting to shareholders a proposal to authorize a potential 1-for-2 to 1-for-5 reverse stock split to help meet Nasdaq listing requirements for the combined company; the company also provided a business update highlighting the full commercial launch of its MyoVista Insights platform, ongoing FDA 510(k) review of its MyoVista wavECG device, and reported Fiscal 2026 results showing no meaningful revenue, $1.7 million in cash, and $0.2 million in shareholders’ equity as of April 30, 2026.

Filing Facts

CIK

1468492

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-082577

Alert Tier

8